Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results.
The actions of trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral mu, kappa and delta opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. Recently, trimebutine has also been shown to decrease reflexes induced by distension of the gut lumen in animals and it may therefore modulate visceral sensitivity. Clinically, trimebutine has proved to be effective in the treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome, at doses ranging from 300 to 600 mg/day. It is also effective in children presenting with abdominal pain.
Delvaux
M
M
Gastroenterology Unit, CHU Rangueil, Toulouse, France.
Wingate
D
D
D015746:Abdominal Pain / Q000188:drug therapy; D000818:Animals; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D004064:Digestive System / Q000187:drug effects / Q000294:innervation; D004068:Digestive System Physiological Phenomena; D004311:Double-Blind Method; D005746:Gastric Emptying / Q000187:drug effects; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D016037:Single-Blind Method; D014287:Trimebutine / Q000494:pharmacology* / Q000592:standards / Q000627:therapeutic use*
D005765:Gastrointestinal Agents; D014287:Trimebutine